CLINICAL TRIALS PROFILE FOR CANCIDAS
✉ Email this page to a colleague
All Clinical Trials for CANCIDAS
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00105144 ↗ | Study of Micafungin in Patients With Invasive Candidiasis or Candidemia | Completed | Astellas Pharma Inc | Phase 3 | 2004-09-01 | The purpose of the study is to determine the safety and effectiveness of two dose levels of micafungin versus caspofungin in the treatment of proven invasive candidiasis or candidemia. |
| NCT00388167 ↗ | Acetato de Caspofungin (Cancidas®) in the Treatment of Fungal Infection | Completed | GTEI | 2004-03-01 | We wanted to determine the efficacy and the safety of caspofungin acetate (CANCIDAS®) in the treatment of invader fungal infection (IFI) specifically, Invasive Candidiasis (CI) in adults patients without neutropenia and Invasive Aspergillosis (AI) in adults patients who are refractory to or intolerant of other therapies (i.e., amphotericin B, lipid formulations of amphotericin B, and/or itraconazole). | |
| NCT00388167 ↗ | Acetato de Caspofungin (Cancidas®) in the Treatment of Fungal Infection | Completed | SEMICYUC | 2004-03-01 | We wanted to determine the efficacy and the safety of caspofungin acetate (CANCIDAS®) in the treatment of invader fungal infection (IFI) specifically, Invasive Candidiasis (CI) in adults patients without neutropenia and Invasive Aspergillosis (AI) in adults patients who are refractory to or intolerant of other therapies (i.e., amphotericin B, lipid formulations of amphotericin B, and/or itraconazole). | |
| NCT00388167 ↗ | Acetato de Caspofungin (Cancidas®) in the Treatment of Fungal Infection | Completed | PETHEMA Foundation | 2004-03-01 | We wanted to determine the efficacy and the safety of caspofungin acetate (CANCIDAS®) in the treatment of invader fungal infection (IFI) specifically, Invasive Candidiasis (CI) in adults patients without neutropenia and Invasive Aspergillosis (AI) in adults patients who are refractory to or intolerant of other therapies (i.e., amphotericin B, lipid formulations of amphotericin B, and/or itraconazole). | |
| NCT00404092 ↗ | Caspofungin Maximum Tolerated Dose in Patients With Invasive Aspergillosis | Completed | University of Cologne | Phase 2 | 2006-10-01 | This study investigates the safety and tolerability as well as the efficacy and pharmacokinetics of caspofungin in four escalating dosages in adult patients with hematologic malignancies and proven or probable invasive aspergillosis. |
| NCT00413218 ↗ | Isavuconazole (BAL8557) in the Treatment of Candidemia and Other Invasive Candida Infections | Completed | Basilea Pharmaceutica | Phase 3 | 2007-03-08 | The purpose of the study is to compare the safety and efficacy of isavuconazole versus caspofungin followed by voriconazole in the treatment of candidemia and other invasive Candida infections. |
| NCT00413218 ↗ | Isavuconazole (BAL8557) in the Treatment of Candidemia and Other Invasive Candida Infections | Completed | Astellas Pharma Inc | Phase 3 | 2007-03-08 | The purpose of the study is to compare the safety and efficacy of isavuconazole versus caspofungin followed by voriconazole in the treatment of candidemia and other invasive Candida infections. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for CANCIDAS
Condition Name
Clinical Trial Locations for CANCIDAS
Trials by Country
Clinical Trial Progress for CANCIDAS
Clinical Trial Phase
Clinical Trial Sponsors for CANCIDAS
Sponsor Name
